Search

Your search keyword '"Staumont‐Sallé, D"' showing total 577 results
Start Over Author "Staumont‐Sallé, D"
577 results on '"Staumont‐Sallé, D"'

3. French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis)

Author

Ingen-Housz-Oro, S., Matei, I., Gaillet, A., Gueudry, J., Zaghbib, K., Assier, H., Hua, C., Bensaid, B., Colin, A., Ouedraogo, R., Redlich, J., Courtois, E., Chazelas, K., Sbidian, E., Nakad, L., Bequignon, E., Terkmane, N., Gaultier, F., Schlemmer, F., Do-Pham, G., Barbaud, A., Lebrun-Vignes, B., Hoffmann, C., Mahé, P.-J., Le Floch, R., Bernier, C., Vabres, B., Milpied, B., Delcampe, A., Tétart, F., Tauber, M., Staumont-Sallé, D., Dezoteux, F., Descamps, V., Misery, L., Bursztejn, A.-C., Dereure, O., Amazan, E., Le Bidre, E., Le Pallec, S., Lagier, C., Laroche, A., Ferrat, E., Wolkenstein, P., and de Prost, N.

Published
2024
Full Text
View/download PDF

4. Promoting clinical research in community-based practice: Threats and opportunities

Author

Poizeau, F., Maruani, A., Staumont-Sallé, D., Jouan, N., Ly, S., Schollhammer, M., Reverte, M., Dibao-Dina, C., Duong, T.-A., Matard, B., Penso-Assathiany, D., Dupuy, A., Carriot, M., Seï, J.-F., Corgibet, F., Guillot, B., Barbarot, S., Leducq, S., Bertolotti, A., Tannous, J., Chaby, G., Jullien, D., Pépin, E., Quéreux, G., Beylot-Barry, M., and Chosidow, O.

Published
2024
Full Text
View/download PDF

5. Promouvoir la recherche clinique en dermatologie libérale : freins et opportunités

Author

Poizeau, F., Maruani, A., Staumont-Sallé, D., Jouan, N., Ly, S., Schollhammer, M., Reverte, M., Dibao-Dina, C., Duong, T.-A., Matard, B., Penso-Assathiany, D., Dupuy, A., Carriot, M., Seï, J.-F., Corgibet, F., Guillot, B., Barbarot, S., Leducq, S., Bertolotti, A., Tannous, J., Chaby, G., Jullien, D., Pépin, E., Quéreux, G., Beylot-Barry, M., and Chosidow, O.

Published
2024
Full Text
View/download PDF

15. Quand mettre en route un traitement systémique dans la dermatite atopique ?

Author

Staumont-Sallé, D.

Abstract

Malgré l’arrivée de nombreux nouveaux traitements dans la dermatite atopique, de nombreux patients, adultes et enfants, restent en errance thérapeutique et ne bénéficient pas d’un traitement suffisant pour contrôler de façon durable leur maladie. Il est dont important d’identifier les patients qui ont besoin d’un traitement systémique quand les traitements topiques ne sont plus adaptés. La décision de mise en route d’un traitement systémique doit reposer sur plusieurs facteurs qui vont bien au-delà de l’AMM et du remboursement d’une molécule. Cette démarche implique en effet une évaluation multidimensionnelle de la sévérité de la maladie, dans laquelle les scores ont une place s’ils sont faisables en pratique et s’ils tiennent compte de la perception qu’a le patient de ses symptômes et du retentissement de la maladie sur sa qualité de vie. La décision médicale partagée permet d’harmoniser les attentes du médecin et du patient (ou de son entourage chez l’enfant) et de définir de manière collaborative un objectif thérapeutique adapté et réaliste. Identifier précocement un patient éligible à un traitement systémique requiert une formation adéquate en soins primaires (médecin traitant, généraliste ou pédiatre) et une bonne coopération ville-hôpital pour le dermatologue ou l’allergologue afin de faciliter le parcours patient et de garantir son accès « au bon traitement au bon moment ».

Published
2024
Full Text
View/download PDF

18. Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce

Author

Bosma, A. L., Musters, A. H., Bloem, M., Gerbens, L. A. A., Middelkamp-Hup, M. A., Haufe, E., Schmitt, J., Barbarot, S., Seneschal, J., Staumont-Sallé, D., Johansson, E. K., Bradley, M., von Kobyletzki, Laura B., Vittrup, I., Ruge, I. Frier, Thyssen, Jacob P., Vestergaard, C., de Vega, M., García-Doval, I., Chiricozzi, A., Stingeni, Luca, Calzavara-Pinton, Piergiacomo, Ardern-Jones, M. R., Reynolds, N. J., Flohr, C., Spuls, P. I., Bosma, A. L., Musters, A. H., Bloem, M., Gerbens, L. A. A., Middelkamp-Hup, M. A., Haufe, E., Schmitt, J., Barbarot, S., Seneschal, J., Staumont-Sallé, D., Johansson, E. K., Bradley, M., von Kobyletzki, Laura B., Vittrup, I., Ruge, I. Frier, Thyssen, Jacob P., Vestergaard, C., de Vega, M., García-Doval, I., Chiricozzi, A., Stingeni, Luca, Calzavara-Pinton, Piergiacomo, Ardern-Jones, M. R., Reynolds, N. J., Flohr, C., and Spuls, P. I.

Abstract

BACKGROUND: the TREatment of ATopic eczema (TREAT) Registry Taskforce is a collaborative international network of registries collecting data of atopic eczema (AE) patients receiving systemic and phototherapy with the common goal to provide long-term real-world data on the effectiveness, safety and cost-effectiveness of therapies. A core dataset, consisting of domains and domain items with corresponding measurement instruments, has been developed to harmonize data collection. OBJECTIVES: we aimed to give an overview of the status and characteristics of the eight established TREAT registries, and to perform a mapping exercise to examine the degree of overlap and pooling ability between the national registry datasets. This will allow us to determine which research questions can be answered in the future by pooling data. METHODS: all eight registries were asked to share their dataset and information on the current status and characteristics. The overlap between the core dataset and each registry dataset was identified (according to the domains, domain items and measurement instruments of the TREAT core dataset). RESULTS AND CONCLUSIONS: a total of 4,702 participants have been recruited in the 8 registries as of 1st of May 2022. Of the 69 core dataset domain items, data pooling was possible for 69 domain item outcomes in TREAT NL (the Netherlands), 61 items in A-STAR (UK and Ireland), 38 items in TREATgermany (Germany), 36 items in FIRST (France), 33 items in AtopyReg (Italy), 29 items in Biobadatop (Spain), 28 items in SCRATCH (Denmark) and 20 items in SwedAD (Sweden). Pooled analyses across all registries can be performed on multiple important domain items, covering the main aims of analyzing data on the (cost-)effectiveness and safety of AE therapies. These results will facilitate future comparative or joint analyses.

Published
2023
Full Text
View/download PDF

19. Retrospective study on the association of human herpesvirus reactivation with severe DRESS: A description of blood and skin reactivations.

Author

Marcombes, C., Ingen‐Housz‐Oro, S., Dezoteux, F., Staumont‐Sallé, D., Milpied, B., Tetart, F., de Prost, N., Fourati, S., Ortonne, N., Kasimir, F., Prusty, B. K., and Descamps, V.

Subjects
INTENSIVE care units, SKIN biopsy, VIRUS reactivation, BLOOD sampling, VIRAL proteins, AUJESZKY'S disease virus
Abstract

Background: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe adverse event (mortality of 10%). Its pathophysiology involves herpesviruses, particularly HHV‐6, but the exact mechanisms are still poorly understood. Objective: To describe severe cases of DRESS and especially their association with herpesvirus reactivation. Methods: This study was a multicentre case series conducted between 2007 and 2021 at five University Hospital Centres in France. The study included patients who had severe DRESS, which was defined as death, transfer to the intensive care unit (ICU), or severe damage to internal organs. We excluded patients without blood PCR sample, without a drug formally attributed or with RegiSCAR score < 6. We collected data on severity, causative drug, associated visceral damage and results of viral blood PCRs. HHV‐6 reactivation was studied in skin biopsies by detection of small non‐coding transcripts (HHV‐6 miR‐aU14) and a late viral protein (GP82/105). Results: Fifty‐two patients were included (29 female, median age 62, interquartile range (IQR) [37;72]). Eight patients (15%) died, 13 (27%) were admitted to ICU. Most patients (n = 34; 65%) had multisystem involvement: most frequent was liver (n = 46; 88%), then renal failure (n = 24; 46%). Forty patients (77%) had at least one blood viral reactivation among HHV‐6, EBV or CMV, of which 21 (53%) had at least two. Median time of blood HHV‐6 reactivation was 24 days (IQR [20;35]). HHV‐6 reactivation was demonstrated in 15 out of 20 skin biopsies, with a median time of 11 days [9;17]. Conclusions: We confirmed the high rate of HHV‐6 reactivation in severe DRESS and demonstrated cutaneous HHV‐6 reactivation using small non‐coding transcripts (HHV‐6 miR‐aU14), which preceded viral PCR positivity in blood. These results suggest that HHV‐6 reactivation during DRESS may start in skin. Furthermore, search for miR‐aU14 in skin biopsy could become a useful diagnostic tool for early detection of HHV‐6 reactivation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Efficacité de l’abrocitinib et du dupilumab sur les taux d’éosinophiles chez les patients atteints de dermatite atopique modérée à sévère et de comorbidités atopiques de type asthme et rhinite allergique : analyse post-hoc de JADE COMPARE

Author

Staumont-Sallé, D., primary, Chan, G., additional, Clibborn, C., additional, Feeney, C., additional, Bourne-Chastel, A., additional, Misery, L., additional, Nosbaum, A., additional, Seneschal, J., additional, Soria, A., additional, and Zhang, F., additional

Published
2022
Full Text
View/download PDF

35. Étude descriptive multicentrique des schémas d’adaptation en cas de réponse inadéquate au dupilumab dans la dermatite atopique en France

Author

Strizzolo, R., primary, Soria, A., additional, Jachiet, M., additional, Tauber, M., additional, Seneschal, J., additional, Clément, A., additional, Staumont-Sallé, D., additional, Barbarot, S., additional, Raison Peyron, N., additional, Viguier, M., additional, Mallet, S., additional, and Du Thanh, A., additional

Published
2022
Full Text
View/download PDF

36. Efficacité et tolérance des inhibiteurs de Janus kinase dans le traitement de la dermatite atopique modérée à sévère de l’adulte réfractaire à d’autres systémiques: expérience en vraie vie

Author

Vanlerberghe, J., primary, Dezoteux, F., additional, Martin, C., additional, Jachiet, M., additional, Soria, A., additional, Tétart, F., additional, Modeste-Duval, A.B., additional, Bursztejn, A.C., additional, Misery, L., additional, Aubin, F., additional, Lasek, A., additional, Leleu, C., additional, Du Thanh, A., additional, Pasteur, J., additional, Pralong, P., additional, Nosbaum, A., additional, Droitcourt, C., additional, Viguier, M., additional, Tauber, M., additional, Seneschal, J., additional, Barbarot, S., additional, and Staumont-Sallé, D., additional

Published
2022
Full Text
View/download PDF

37. Impact de la dermatite atopique sur les conjoints des patients

Author

Misery, L., primary, Seneschal, J., additional, Corgibet, F., additional, Halioua, B., additional, Marquie, A., additional, Merhand, S., additional, Le Fur, G., additional, Bergqvist, C., additional, Taieb, C., additional, Staumont-Sallé, D., additional, Ezzedine, K., additional, and Richard, M.A., additional

Published
2022
Full Text
View/download PDF

39. Eczéma paradoxal sous biothérapie ciblant l’axe IL-5/IL-5R

Author

Bourdenet, V., primary, Devouassoux, G., additional, Antoine, B., additional, Bernier, C., additional, Carpentier, O., additional, Chenivesse, C., additional, Du Thanh, A., additional, Fry, S., additional, Gadiolet, Y., additional, Gamez, A.S., additional, Kelkel, E., additional, Larousse, M., additional, Soria, A., additional, Staumont-Sallé, D., additional, Streker, A., additional, Valois, A., additional, Xavier, B., additional, Freymont, N., additional, and Nosbaum, A., additional

Published
2022
Full Text
View/download PDF

46. Étude de survie du traitement par omalizumab dans une cohorte multicentrique française de patients atteints d’urticaire chronique

Author

Litovsky, J., primary, Paryl, M., additional, Hacard, F., additional, Tétart, F., additional, Boccon Gibod, I., additional, Dezoteux, F., additional, Staumont-Sallé, D., additional, Darrigade, A.S., additional, Doutre, M.S., additional, Milpied, B., additional, Soria, A., additional, Amsler, E., additional, Bernier, C., additional, Perrot, J.L., additional, Raison Peyron, N., additional, Mura, T., additional, Grosjean, J., additional, and Du Thanh, A., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results